Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EPS (Basic): 2021-2025

Historic EPS (Basic) for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$0.32.

  • Prime Medicine's EPS (Basic) rose 27.27% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 30.10%. This contributed to the annual value of -$1.65 for FY2024, which is 24.31% up from last year.
  • Latest data reveals that Prime Medicine reported EPS (Basic) of -$0.32 as of Q3 2025, which was up 21.95% from -$0.41 recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's EPS (Basic) peaked at $0.72 during Q4 2022, and registered a low of -$4.45 during Q4 2021.
  • Its 3-year average for EPS (Basic) is -$0.45, with a median of -$0.44 in 2024.
  • Per our database at Business Quant, Prime Medicine's EPS (Basic) surged by 116.18% in 2022 and then tumbled by 200.00% in 2023.
  • Quarterly analysis of 5 years shows Prime Medicine's EPS (Basic) stood at -$4.45 in 2021, then skyrocketed by 116.18% to $0.72 in 2022, then slumped by 200.00% to -$0.72 in 2023, then spiked by 56.94% to -$0.31 in 2024, then rose by 27.27% to -$0.32 in 2025.
  • Its EPS (Basic) was -$0.32 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.40 in Q1 2025.